MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3; MGA012, an anti-PD-1 monoclonal antibody, which inhibits programmed cell death protein 1 (PD-1); MGD013, a monoclonal antibody that targets the immune checkpoints PD-1 and lymphocyte-activation gene 3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and Enoblituzumab, a monoclonal antibody that targets B7-H3. In addition, the company is developing MGD009, a DART molecule that targets B7-H3 expressed on tumor cells and CD3; MGC018, an antibody drug conjugate, which targets solid tumors expressing B7-H3; and MGD007, a DART molecule, which targets glycoprotein A33 and CD3; and MGD014, a DART molecule that targets virus-infected cells. It has strategic collaborations with Incyte Corporation; Les Laboratoires Servier and Institut de Recherches Servier; and Zai Lab Limited. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone301-251-5172
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$60.12 million
Profitability
Miscellaneous
Employees364
Next Earnings Date5/6/2019 (Estimated)
OptionableOptionable
MacroGenics (NASDAQ:MGNX) Frequently Asked Questions
What is MacroGenics' stock symbol?
MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."
How were MacroGenics' earnings last quarter?
MacroGenics Inc (NASDAQ:MGNX) announced its earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($1.03) earnings per share for the quarter, topping the Zacks' consensus estimate of ($1.20) by $0.17. The biopharmaceutical company earned $18.83 million during the quarter, compared to analyst estimates of $4.41 million. MacroGenics had a negative net margin of 285.18% and a negative return on equity of 63.22%. View MacroGenics' Earnings History.
When is MacroGenics' next earnings date?
What price target have analysts set for MGNX?
12 Wall Street analysts have issued 12-month price targets for MacroGenics' shares. Their forecasts range from $20.00 to $50.00. On average, they expect MacroGenics' share price to reach $32.78 in the next year. This suggests a possible upside of 102.2% from the stock's current price. View Analyst Price Targets for MacroGenics.
What is the consensus analysts' recommendation for MacroGenics?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 4 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MacroGenics.
What are Wall Street analysts saying about MacroGenics stock?
Here are some recent quotes from research analysts about MacroGenics stock:
- 1. HC Wainwright analysts commented, "Our 12-month, $39 price target for shares of MacroGenics is based on a 12-year DCF-driven sum-of-the-parts analysis. Our DCF is driven by: beta of 1.75, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 11.5%, and tax rate of 15% beginning in FY 2027. and flotetuzumab (16%) together represent our full target. Risks potentially incurred investing in this stock include: clinical and development, financial, regulatory and reimbursement, and commercial." (4/4/2019)
- 2. According to Zacks Investment Research, "MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. " (3/1/2019)
Has MacroGenics been receiving favorable news coverage?
Media coverage about MGNX stock has trended neutral this week, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. MacroGenics earned a media sentiment score of 0.4 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term.
Are investors shorting MacroGenics?
MacroGenics saw a decline in short interest in March. As of March 29th, there was short interest totalling 3,377,260 shares, a decline of 33.6% from the March 15th total of 5,084,858 shares. Based on an average trading volume of 735,268 shares, the short-interest ratio is presently 4.6 days. Currently, 7.9% of the shares of the stock are sold short. View MacroGenics' Current Options Chain.
Who are some of MacroGenics' key competitors?
Some companies that are related to MacroGenics include Global Blood Therapeutics (GBT), Amicus Therapeutics (FOLD), Emergent Biosolutions (EBS), Biohaven Pharmaceutical (BHVN), Intercept Pharmaceuticals (ICPT), Ligand Pharmaceuticals (LGND), Akcea Therapeutics (AKCA), Reata Pharmaceuticals (RETA), Insmed (INSM), Portola Pharmaceuticals (PTLA), Mirati Therapeutics (MRTX), Arena Pharmaceuticals (ARNA), PTC Therapeutics (PTCT), The Medicines (MDCO) and Uniqure (QURE).
What other stocks do shareholders of MacroGenics own?
Who are MacroGenics' key executives?
MacroGenics' management team includes the folowing people:
- Dr. Scott Koenig, CEO, Pres & Director (Age 67)
- Mr. James Karrels, Sr. VP, CFO & Sec. (Age 52)
- Dr. Ezio Bonvini, Sr. VP of Research & Chief Scientific Officer (Age 65)
- Mr. Eric Blasius Risser, Sr. VP of Bus. Devel. & Portfolio Management and Chief Bus. Officer (Age 46)
- Dr. Jon M. Wigginton, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 57)
Who are MacroGenics' major shareholders?
MacroGenics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (1.98%), Strs Ohio (0.08%) and Virtu Financial LLC (0.02%). Company insiders that own MacroGenics stock include Eric Blasius Risser, James Karrels, Jeffrey Stuart Peters, Jon Marc Wigginton, Lynn Cilinski, Matthew K Fust and Thomas Spitznagel. View Institutional Ownership Trends for MacroGenics.
Which institutional investors are selling MacroGenics stock?
MGNX stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio. Company insiders that have sold MacroGenics company stock in the last year include Jeffrey Stuart Peters, Matthew K Fust and Thomas Spitznagel. View Insider Buying and Selling for MacroGenics.
Which institutional investors are buying MacroGenics stock?
How do I buy shares of MacroGenics?
Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MacroGenics' stock price today?
One share of MGNX stock can currently be purchased for approximately $16.21.
How big of a company is MacroGenics?
MacroGenics has a market capitalization of $791.05 million and generates $60.12 million in revenue each year. The biopharmaceutical company earns $-171,450,000.00 in net income (profit) each year or ($4.19) on an earnings per share basis. MacroGenics employs 364 workers across the globe.
What is MacroGenics' official website?
How can I contact MacroGenics?
MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at 301-251-5172.
MarketBeat Community Rating for MacroGenics (NASDAQ MGNX)
MarketBeat's community ratings are surveys of what our community members think about MacroGenics and other stocks. Vote "Outperform" if you believe MGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
